Organic Letters · 2013 · 77 citations · 15 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryDrug MetabolismDrug DispositionDrug-metabolizing EnzymesMetabolic Stability EnhancementMetabolic Stability OptimizationPharmacokinetic OptimizationChemical Synthesis Of AnaloguesIn-vitro CharacterizationLenalidomide TherapyMedication TeratogenicityPharmaceutical TeratogenicityPlasma Stability AssaysPlasma Stability ImprovementThalidomide Analogs
Oxetanes are used in drug discovery to enable physicochemical and metabolic property enhancement for the structures to which they are grafted. An imide C═O to oxetane swap on thalidomide and lenalidomide templates provides analogs with similar physicochemical and in vitro properties of the parent drugs, with an important exception: oxetane analog 2 displays a clear differentiation with respect to human plasma stability. The prospect of limiting in vivo stability/metabolism, blocking in vivo racemization, and potentially altering teratogenicity is appealing.
15
Thalidomide is an inhibitor of angiogenesis.
Robert J. D’Amato, Michael Loughnan, Evelyn Flynn et al. · Proceedings of the National Academy of Sciences · 1994 · 2.5K citations
Identification of a Primary Target of Thalidomide Teratogenicity
Takumi Ito, Hideki Ando, Takayuki Suzuki et al. · Science · 2010 · 2.1K citations
Thalidomide in the treatment of lepra reactions
J Sheskin · Clinical Pharmacology & Therapeutics · 1965 · 533 citations
Oxetanes in Drug Discovery: Structural and Synthetic Insights
Georg Wuitschik, Erick M. Carreira, Björn Wagner et al. · Journal of Medicinal Chemistry · 2010 · 405 citations